Page 32 - Annual Report 2020
P. 32
Shujun Liu, Ph.D.
Cancer Epigenetics and Experimental Therapeutics
SECTION LEADER / ASSOCIATE PROFESSOR
“Overall, our discov- eries offer new insights into the molecular biology of cancer pathogenesis and drug resistance, identify new prognostic biomarkers and therapeutic targets, and develop novel therapeutic reagents to improve
the management of
cancerous lesions.”
Shujun Liu
Bing Bai Bei Liu Ning Xiang
JiuXia Pang Ludong Tan Xiaochang Liu
Our research goal is to investigate the causes and outcomes of aberrant lysine methyl- ation of non-histone proteins and mRNA
N6-Methyladenosine in cancer pathogenesis and drug resistance. To achieve our goal, we used a multidisciplinary approach with molecular biology, animal models and human Biospecimens, and made significant achievements outlined below.
Discover the FTO-N6-Methyladenosine axis as a key regulator for leukemia drug resistance
The N6-methyladenosine (m6A) is the most com- mon epitranscriptomic modification on mRNA, which critically regulates gene expression at the post-transcriptional levels and displays dynamic and reversible features. We hypothesize that upon exposure to tyrosine kinase inhibitors (TKIs), the
SUMMARY
^
